These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Development of aromatase inhibitors and analysis of their inhibitory activities].
    Author: Numazawa M.
    Journal: Yakugaku Zasshi; 1998 Dec; 118(12):539-53. PubMed ID: 9921263.
    Abstract:
    Inhibitors of aromatase are of interest in the treatment of advanced estrogen-dependent breast cancers. In addition, the inhibitors are promising to play as conformational and catalytic probes for the active site of this enzyme, aromatase. There fore, we synthesized a number of steroidal aromatase inhibitors, including suicide substrates, and also studied the mechanism for a time-dependent inactivation of aromatase by the suicide substrates. The mechanism for the aromatase inactivation by 6-oxo-androstenedione (AD) (1), one of the first discovered suicide substrates, was explored using the 19-substituted analogs 2-5 as well as stereo- and/or regio-specifically labeled [3H, 14C]-compound 1. The results indicated that the 4 beta,5 beta-epoxy-19-oxo derivative 7 is a reactive electrophile that irreversibly binds to the active site of aromatase. Studies on the aromatase inhibition by regioisomers of AD, 4-en-6-one 17, 5-en-4-one 18 and 5-en-7-one 19, revealed that the C-3 carbonyl function is not essential for the tight binding of an inhibitor to the active site. 3-Deoxy AD (22) and its 6 alpha,7 alpha-cyclopropano steroid 24 as well as some of 6-alkyl-ADs are among the most potent competitive inhibitors reported so for (K(m) for AD/Ki > 6). Structure-activity relationships of the 6-alkyl-ADs and their 3-deoxy-, delta 1-, delta 6-, and delta 1,6-analogs as aromatase inhibitors showed that aromatase has a hydrophobic binding pocket with a limited accessible volume in the active site in the region corresponding to the beta-side rather than the alpha-side of the C-6 position of the substrate. The 6-alkyl-ADs and their delta 1-analogs were converted into the corresponding estrogens with human placental aromatase, whereas the 3-deoxy steroids 22 and 25 were metabolized to the corresponding 19-oxygenated compounds. The relative apparent K(m) values for the androgens are different from the relative Ki values, indicating that there is a difference between the ability to serve as an inhibitor and that to serve as a substrate. Moreover, it seems likely that the alignment of the substrate AD analogs in the active site would be markedly different from that of the 3-deoxy steroids.
    [Abstract] [Full Text] [Related] [New Search]